Haemonetics downgraded to Neutral from Buy at Citi

Citi downgraded Haemonetics (HAE) to Neutral from Buy with a price target of $88, up from $77. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is “bouncing off its lows,” and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index “remains undervalued and underappreciated.” The firm expects a rebound next year due to company catalysts and sector rotation.